10x Genomics ROCE
What is the ROCE of 10x Genomics?
The ROCE of 10x Genomics, Inc. is -28.49%
What is the definition of ROCE?
Return on capital employed (ROCE) is a financial ratio that measures a company’s profitability and the efficiency with which its capital is used.
= EBIT / (assets - current liabilities)
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE of companies in the Health Care sector on NASDAQ compared to 10x Genomics
What does 10x Genomics do?
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Companies with roce similar to 10x Genomics
- Cranstown Capital has ROCE of -28.64%
- Alnylam Pharmaceuticals has ROCE of -28.63%
- Alnylam Pharmaceuticals has ROCE of -28.63%
- Veteran Capital has ROCE of -28.62%
- Ovid Therapeutics Inc has ROCE of -28.61%
- UCapital24 S.p.A has ROCE of -28.60%
- 10x Genomics has ROCE of -28.49%
- SimiGon has ROCE of -28.47%
- Trillium Therapeutics Inc has ROCE of -28.46%
- A.K.A. Brands has ROCE of -28.41%
- Megalith has ROCE of -28.39%
- Direct Selling Acquisition has ROCE of -28.37%
- Xcel Brands Inc has ROCE of -28.32%